Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease

Liver International

Volumn 31, Issue 2, 2011, Pages 176-183

  Kotronen, Anna ^a,b   Joutsi Korhonen, Lotta ^c   Sevastianova, Ksenia ^a,b   Bergholm, Robert ^a,b   Hakkarainen, Antti ^a   Pietiläinen, Kirsi H ^a   Lundbom, Nina ^a   Rissanen, Aila ^a   Lassila, Riitta ^c   Yki Järvinen, Hannele ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Activated partial thromboplastin time; Coagulation factor VIII; Fibrinogen; Insulin resistance; IX; Metabolic syndrome; Obesity; Prothrombin time; Proton magnetic resonance spectroscopy; Von Willebrand factor; XI; XII

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; D DIMER; FIBRINOGEN; PROTHROMBIN; VON WILLEBRAND FACTOR;

ADULT; AGE; AGED; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BODY COMPOSITION; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; GENDER; HUMAN; INSULIN RESISTANCE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PARTIAL THROMBOPLASTIN TIME; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTON NUCLEAR MAGNETIC RESONANCE; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; VENOUS THROMBOEMBOLISM;

ADULT; AGE FACTORS; AGED; BODY MASS INDEX; FACTOR IX; FACTOR VIII; FACTOR XI; FACTOR XII; FATTY LIVER; FEMALE; FIBRINOGEN; FINLAND; HUMANS; INSULIN RESISTANCE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN; SEX FACTORS; VON WILLEBRAND FACTOR;

EID: 78650777773     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02375.x     Document Type: Article

References (55)

1. Stein PD, Goldman J. Obesity and thromboembolic disease. Clin Chest Med 2009; 30: 489-93, viii.
2. Dentali F, Squizzato A, Ageno W. The metabolic syndrome as a risk factor for venous and arterial thrombosis. Semin Thromb Hemost 2009; 35: 451-7.
3. Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen city heart study. Circulation 2010; 121: 1896-903.
4. Bertina RM. Elevated clotting factor levels and venous thrombosis. Pathophysiol Haemost Thromb 2003; 33: 395-400.
5. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the united states. Am J Gastroenterol 2003; 98: 960-7.
6. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the united states: impact of ethnicity. Hepatology 2004; 40: 1387-95.
7. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28: 629-36.
8. Edens MA, Kuipers F, Stolk RP. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes Rev 2009; 10: 412-9.
9. Cigolini M, Targher G, Agostino G, et al. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men - role of the metabolic syndrome. Thromb Haemost 1996; 76: 69-73.
10. Kargili A, Cipil H, Karakurt F, et al. Hemostatic alterations in fatty liver disease. Blood Coagul Fibrinolysis 2010; 21: 325-7.
11. Targher G, Bertolini L, Scala L, et al. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med 2005; 22: 1354-8.
12. Papatheodoridis GV, Chrysanthos N, Cholongitas E, et al. Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease. J Hepatol 2009; 51: 931-8.
13. Assy N, Bekirov I, Mejritsky Y, et al. Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. World J Gastroenterol 2005; 11: 5834-9.
14. Hickman IJ, Sullivan CM, Flight S, et al. Altered clot kinetics in patients with non-alcoholic fatty liver disease. Ann Hepatol 2009; 8: 331-8.
15. van der Boogaart A, van Hecke A, van Huffel P, et al. MRUI: a graphical user interface for accurate routine MRS data analysis. Proceedings of the ESMRMB, 13th Annual Meeting, 1996, p. 318.
16. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997; 129: 35-43.
17. Stanisz GJ, Odrobina EE, Pun J, et al. T1, T2 relaxation and magnetization transfer in tissue at 3T. Magn Reson Med 2005; 54: 507-12.
18. Graham SJ, Stanisz GJ, Kecojevic A, Bronskill MJ, Henkelman RM. Analysis of changes in MR properties of tissues after heat treatment. Magn Reson Med 1999; 42: 1061-71.
19. Longo R, Pollesello P, Ricci C, et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 1995; 5: 281-5.
20. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: E462-8.
21. Szczepaniak LS, Babcock EE, Schick F, et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol 1999; 276: E977-89.
22. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366: 1059-62.
23. Kadish AH, Little RL, Sternberg JC. A new and rapid method for the determination of glucose by measurement of rate of oxygen consumption. Clin Chem 1968; 14: 116-31.
24. Marti B, Tuomilehto J, Salomaa V, et al. Body fat distribution in the Finnish population: environmental determinants and predictive power for cardiovascular risk factor levels. J Epidemiol Community Health 1991; 45: 131-7.
25. Schwenzer NF, Springer F, Schraml C, et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51: 433-45.
26. Stel HV, van der Kwast TH, Veerman EC. Detection of factor VIII/coagulant antigen in human liver tissue. Nature 1983; 303: 530-2.
27. Egeberg O. Clotting factor levels in patients with coronary atherosclerosis. Scand J Clin Lab Invest 1962; 14: 253-8.
28. Sugrue DD, Trayner I, Thompson GR, et al. Coronary artery disease and haemostatic variables in heterozygous familial hypercholesterolaemia. Br Heart J 1985; 53: 265-8.
29. de Lange M, Snieder H, Ariens RA, et al. The relation between insulin resistance and hemostasis: pleiotropic genes and common environment. Twin Res 2003; 6: 152-61.
30. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb 1993; 13: 1865-73.
31. Luxembourg B, Schmitt J, Humpich M, et al. Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: a focus on fibrinogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP). Thromb Haemost 2009; 102: 668-75.
32. Schambeck CM, Grossmann R, Zonnur S, et al. High factor VIII (FVIII) levels in venous thromboembolism: role of unbound FVIII. Thromb Haemost 2004; 92: 42-6.
33. Passaro A, Calzavarini S, Volpato S, et al. Reduced factor VII and factor VIII levels and prolonged thrombin-generation times during a healthy diet in middle-aged women with mild to moderate cardiovascular disease risk. J Thromb Haemost 2008; 6: 2088-94.
34. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 27-38.
35. Saenko EL, Ananyeva N, Kouiavskaia D, et al. Molecular defects in coagulation factor VIII and their impact on factor VIII function. Vox Sang 2002; 83: 89-96.
36. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European concerted action on thrombosis and disabilities angina pectoris study group. N Engl J Med 1995; 332: 635-41.
37. Jansson JH, Nilsson TK, Johnson O. Von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-5.
38. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6: 217-46.
39. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-4.
40. Barillari G, Fabbro E, Pasca S, Bigotto E. Coagulation and oxidative stress plasmatic levels in a type 2 diabetes population. Blood Coagul Fibrinolysis 2009; 20: 290-6.
41. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89: 493-8.
42. Wannamethee SG, Whincup PH, Rumley A, Lowe GD. Inter-relationships of interleukin-6, cardiovascular risk factors and the metabolic syndrome among older men. J Thromb Haemost 2007; 5: 1637-43.
43. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-8.
44. Angulo P. Obesity and nonalcoholic fatty liver disease. Nutr Rev 2007; 65: S57-63.
45. Haukeland JW, Aukrust P. Inflammatory interactions between nonalcoholic fatty liver disease and the metabolic syndrome. J Hepatol 2006; 45: 881-2.
46. Haukeland JW, Damas JK, Konopski Z, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006; 44: 1167-74.
47. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood 2006; 108: 4045-51.
48. Yang DT, Flanders MM, Kim H, Rodgers GM. Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events. Am J Clin Pathol 2006; 126: 411-5.
49. Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008; 111: 4113-7.
50. Yamashita A, Nishihira K, Kitazawa T, et al. Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery. J Thromb Haemost 2006; 4: 1496-501.
51. Gruber A, Hanson SR. Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood 2003; 102: 953-5.
52. Sugatani J, Wada T, Osabe M, et al. Dietary inulin alleviates hepatic steatosis and xenobiotics-induced liver injury in rats fed a high-fat and high-sucrose diet: association with the suppression of hepatic cytochrome P450 and hepatocyte nuclear factor 4alpha expression. Drug Metab Dispos 2006; 34: 1677-87.
53. Tarumi T, Kravtsov DV, Zhao M, Williams SM, Gailani D. Cloning and characterization of the human factor XI gene promoter: transcription factor hepatocyte nuclear factor 4alpha (HNF-4alpha) is required for hepatocyte-specific expression of factor XI. J Biol Chem 2002; 277: 18510-6.
54. Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res 1999; 94: 271-305.
55. Dunn EJ, Philippou H, Ariens RA, Grant PJ. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006; 49: 1071-80.